A combinatorial approach targeting CD73 and IDO could potentially enhance the AML CAR T therapy; in this regard, our group is integrating universal off-the-shelf CLL-1 CAR T cells and several nanocarriers to deliver CD73 short hairpin (shRNA) and miRNA-135 as promising strategies for targeting CD73 and IDO, respectively. Here, IDO1 is linked to B-cell chronic lymphocytic leukemia.